TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22607269
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of S1RA (50-400 mg once daily for 8 days, study 102)
Study: 18590952
Drug: Fenfluramine administration
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine administration in MDD/AUD group
Study: 12215958
Drug: Intravenous L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-arginine hydrochloride salt
Study: 9641434
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg orally twice per day)
Study: 15378949
Drug: alpha-interferon (alpha-IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alpha-interferon (alpha-IFN) administered at a dose of 3 x 10(6) U three times per week until disease progression.
Study: 15378949
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (control group) for patients who obtained a complete or partial response after FLU therapy.
Study: 1099894
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g D-isoascorbic acid
Study: 2110943
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g L-ascorbic acid
Study: 31773143
Drug: Fidaxomicin (suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin (suspension or tablets, twice daily for 10 days)
Study: 31773143
Drug: Vancomycin (suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (suspension or tablets, 4 times daily for 10 days)
Study: 26399399
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture plus as-needed salbutamol aerosol and/or prednisone tablets
Study: 26399399
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture plus as-needed salbutamol aerosol and/or prednisone tablets
Study: 23290835
Drug: VPM1002 (Mycobacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPM1002 (Mycobacterium bovis BCG ΔureC::hly Hm(R)), administered as one intradermal dose, randomized to three escalating doses.
Study: 7714143
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (Ig) 500 mg/kg prior to the next embryo transfer
Study: 3443063
Drug: Felodipine 10mg
Normalized name: FELODIPINE 10MG TAB,SA
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 10mg single dose
Study: 3443063
Drug: Felodipine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (various doses)
Study: 31248662
Drug: Veverimer (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veverimer (6 g/day)
Study: 29235659
Drug: Open‐label, protocolized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open‐label, protocolized treatment with extended‐release venlafaxine for 12 or more weeks
Study: 25145693
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral methylprednisolone (oMP)
Study: 19015193
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (5K(Plac), L3‐L4)
Study: 11549975
Drug: Low-dose fluticasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluticasone propionate (176 or 200 mcg daily) for 6‐26 weeks
Study: 11549975
Drug: Low-dose fluticasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluticasone propionate (100 mcg daily) for 12‐52 weeks
Study: 11549975
Drug: Low-dose beclomethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose beclomethasone dipropionate (336 mcg daily)
Study: 7964957
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa 3 MU three times weekly
Study: 7964957
Drug: IFN alfa
Normalized name: IFN Alfacon-1
DrugBank: Interferon alfacon-1 (DB00069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alfa 5 MU three times weekly plus DEX
Study: 7964957
Drug: Higher dose-intensity
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher dose-intensity glucocorticoids
Study: 3655306
Drug: Repeated paracentesis
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated paracentesis plus i.v. albumin infusion (n = 20)
Study: 3655306
Drug: Diuretics (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (n = 21)
Study: 29788137
Drug: TELE‐IBD W
Approvals — FDA: no, EMA: no, PMDA: no
Description: TELE‐IBD W (weekly)
Study: 22519127
Drug: Inhaled fluticasone/salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone/salmeterol (group A)
Study: 22519127
Drug: Inhaled budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide/formoterol (group B)
Study: 20691689
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg CDC
Study: 20691689
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg CDC
Study: 16538529
Drug: Tamoxifen (Tam)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (Tam) 20 mg per day orally for 5 years
Study: 16538529
Drug: Tamoxifen (Tam)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (Tam) plus Fluoxymesterone (Flu) 10 mg orally twice per day for 1 year
Study: 12654164
Drug: Isolated isoflavone
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated isoflavone supplement (86 mg/d, derived from red clover)
Study: 31049414
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care at public health facilities including clinical care guides, drugs for COPD, patient education flipcharts, staff training, and mobile phone follow-up.
Study: 28118538
Drug: Peficitinib 50
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 50 mg
Study: 28118538
Drug: Peficitinib 100
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 100 mg
Study: 28118538
Drug: Peficitinib 150
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 150 mg
Study: 26672064
Drug: All peficitinib
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All peficitinib doses (25, 50, 100, 150 mg)
Study: 28118538
Drug: Peficitinib 25
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 25 mg
Study: 17628451
Drug: LDE tablet
Normalized name: LANCET,STERILANCE LDE 2 DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE tablet of griseofulvin (125mg)
Study: 17628451
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release conventional tablet of griseofulvin (125mg)
Study: 14556131
Drug: Neostigmine 1
Normalized name: neostigmine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 1 mg added to 3 mg/kg of 0.5% lidocaine (maximum 45 mL)
Study: 14556131
Drug: No additives
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additives to the IVRA solution (Control group)
Study: 10364900
Drug: SASP 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: SASP 2000 (maximum 3000) mg daily (n = 68)
Study: 10364900
Drug: MTX 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX 7.5 (maximum 15) mg weekly (n = 69)
Study: 9345416
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous immunoglobulin (IVIG)
Study: 27221477
Drug: Artificial cycle
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial cycle with GnRH-agonist (n=118)
Study: 22189672
Drug: EGb 761®
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761® 120 mg twice daily
Study: 22189672
Drug: EGb 761®
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761® 240 mg once daily
Study: 20629597
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 100 microg daily for 4 weeks
Study: 11795350
Drug: Raloxifene (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (selective estrogen receptor modulator)
Study: 9018407
Drug: Water‐Del (metered:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water‐Del (metered: 200 ml water every 15 min)
Study: 18296460
Drug: Antioxidants (selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (selenium 10 mug, zinc 5 mg, vitamin A 0.9 mg, vitamin E 100 mg, vitamin C 50 mg)
Study: 18296460
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (0.1 mg)
Study: 12709801
Drug: Faropenem daloxate
Normalized name: Faropenem daloxate
DrugBank: Faropenem medoxomil (DB05659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faropenem daloxate (300 mg, twice daily for 7 days)
Study: 12709801
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (250 mg, twice daily for 7 days)
Study: 9112443
Drug: Pion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pion therapy (33-34.5 Gy pi)
Study: 1287620
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF 500 mg once daily (at night)
Study: 1287620
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg three times a day
Study: 1287620
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF (375 mg and 500 mg)
Study: 6961477
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 in viscous gel
Study: 26272450
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral fimasartan (FMS)
Study: 26272450
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous (IV) fimasartan (FMS)
Study: 23027677
Drug: Acute 1-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute 1-mg dose of alprazolam
Study: 10210759
Drug: Moderate effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate effect of treatments
Study: 8896514
Drug: B‐C7 (anti‐TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐C7 (anti‐TNF monoclonal antibody)
Study: 6684468
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg X day‐1 for 5 consecutive days
Study: 22936524
Drug: PDA, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA, daily tailored feedback messages (PDA + FB)
Study: 22936524
Drug: PDA, no-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA, no-daily feedback
Study: 22936524
Drug: paper diary
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: paper diary (PD), no-daily feedback
Study: 21976939
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) 80 mg orally, twice a day for four weeks
Study: 21976939
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice a day for four weeks
Study: 15875189
Drug: Nasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal salmon calcitonin 100 IU day(‐1), 1,000 mg day(‐1) elemental calcium, 400 IU day(‐1) vitamin D
Study: 15875189
Drug: Placebo (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1,000 mg day(‐1) elemental calcium, 400 IU day(‐1) vitamin D)
Study: 11930591
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ribavirin and interferon alfa-2b
Study: 31636243
Drug: 1 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg/kg dexmedetomidine plus local infiltration of 0.2 ml/kg bupivacaine 0.5% (BD)
Study: 30298411
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) - two placebo tablets twice daily for 3 weeks
Study: 19686477
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% (1.5 ml) with fentanyl (0.3 ml, 15 microg)
Study: 19686477
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (1.5 ml) with fentanyl (0.3 ml, 15 microg)
Study: 17452505
Drug: Trandolapril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (4 mg per day)
Study: 15054428
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg vitamin C
Study: 15054428
Drug: 7500 mg
Normalized name: sodium sulfate 7500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7500 mg vitamin C
Study: 7910089
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine with 69‐kd membrane protein (CP4)
Study: 7910089
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine without 69‐kd membrane protein (CP5)
Study: 7910089
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine combined with diphtheria and tetanus toxoids (CP4DT or CP5DT)
Study: 7910089
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (CP5DT) for 4‐ to 6‐year‐old children
Study: 3309829
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefotiam pre-operative antibioprophylaxis
Study: 29872876
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alpha 2-a (PEG-IFN α-2a) therapy
Study: 25822572
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1 mL of methylprednisolone acetate, 40 mg/mL, dissolved in 4 mL of lidocaine hydrochloride, 10 mg/mL)
Study: 25822572
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (1 mL isotonic saline mixed with 4 mL of lidocaine hydrochloride, 10 mg/mL)
Study: 24430056
Drug: Lantoks injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lantoks injections in spastic muscles
Study: 24430056
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (massage, exercise therapy, FTL, pharmacotherapy)
Study: 10984564
Drug: Inactivated-poliovirus vaccine
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated-poliovirus vaccine (IPV), administered subcutaneously
Study: 9076288
Drug: Letter of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letter of invitation for a flu vaccine
Study: 9076288
Drug: Offer of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Offer of a free flu vaccine
Study: 27816913
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture (4 joules/cm², total dose = 40 joules)
Study: 23962386
Drug: Skin and
Normalized name: Hair Skin and Nails
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin and subcutaneous fat thickness
Study: 7733122
Drug: Acarbose 200
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 200 mg
Study: 20066964
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg with sucrose
Study: 20066964
Drug: Acarbose 200
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 200 mg with sucrose
Study: 15083524
Drug: Lorazepam (single-dose)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam (single-dose)
Study: 25670362
Drug: Anacetrapib 100
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 100 mg/day
Study: 16753373
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg bicalutamide daily
Study: 9829605
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) supplementation (0.15 mg/kg/d) during total parenteral nutrition (TPN)
Study: 2688065
Drug: Sucralfate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (4 g)
Study: 2688065
Drug: Prednisolone metasulphobenzoate
Normalized name: prednisolone sodium metasulphobenzoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone metasulphobenzoate (20 mg)
Study: 5310209
Drug: Amantadine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100 mg twice daily for 20 days)
Study: 23389298
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (Gln)
Study: 21778352
Drug: Gemfibrozil 30
Normalized name: gemfibrozil 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 30 mg
Study: 21778352
Drug: Gemfibrozil 100
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil 100 mg
Study: 21778352
Drug: Gemfibrozil 300
Normalized name: gemfibrozil 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 300 mg
Study: 21778352
Drug: Gemfibrozil 900
Normalized name: gemfibrozil 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 900 mg
Study: 18623910
Drug: Recombinant parathyroid
Normalized name: Recombinant parathyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant parathyroid hormone
Study: 16495253
Drug: FPV 1,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV 1,400 mg BID plus RTV 100 mg BID
Study: 16495253
Drug: FPV 1,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV 1,400 mg BID plus RTV 200 mg BID
Study: 16495253
Drug: FPV 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV 700 mg BID plus RTV 100 mg BID
Study: 11482295
Drug: Computerized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized treatment simulation presentation
Study: 11482295
Drug: Treatment simulation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment simulation group
Study: 27230437
Drug: Real-time medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time medication monitoring (RTMM) with tailored SMS reminders
Study: 22726281
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg once daily)
Study: 22726281
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg twice daily)
Study: 19473334
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration after mail administration
Study: 19473334
Drug: Mail administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mail administration first
Study: 19473334
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration first
Study: 12476290
Drug: Alanyl-glutamine dipeptide
Normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl-glutamine dipeptide (30 g i.v. from day +1 to day +14)
Study: 7599546
Drug: Morphine combined
Normalized name: morphine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine combined with bupivacaine injected into the knee joint
Study: 31849085
Drug: Albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusion (8 g/dL of ascitic fluid; n = 40)
Study: 30884808
Drug: SAx (Hydroxytyrosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAx (Hydroxytyrosol 9.9 mg and Punicalagin 195 mg)
Study: 15377355
Drug: Two-compound product
Normalized name: Ceo-Two Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound product (TCP) containing calcipotriol (50 microg g(‐1)) and betamethasone dipropionate (0.5 mg g(‐1)) applied once or twice daily
Study: 15377355
Drug: Calcipotriol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (50 microg g(‐1)) applied twice daily
Study: 15377355
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) applied twice daily
Study: 15377355
Drug: TCP applied
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCP applied once daily
Study: 15377355
Drug: Calcipotriol applied
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol applied twice daily
Study: 15377355
Drug: TCP applied
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCP applied twice daily
Study: 11409676
Drug: Complete implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete implant stabilised oral prostheses (IG)
Study: 6685644
Drug: low-dose chemotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose chemotherapy (lmfp)
Study: 24472854
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention (n=1736)